What's Behind The Big Stock Moves? BDSX, APLM, RNAZ...

Several biotech and animal health companies are experiencing notable stock movements: Biodesix (BDSX) surged over 80% following a 21% revenue increase to $18.0 million in Q1 2025 and narrowed net losses, with full-year revenue projected between $80-$85 million; Apollomics Inc. (APLM) is up nearly 30% after a collaboration with LaunXP, receiving $10 million upfront and potential milestones up to $50 million; Immuncell Corporation (ICCC) rose over 14% after reporting record product sales of $8.1 million in Q1 2025, with net income improving to $1.4 million; Semler Scientific (SMLR), a corporate bitcoin holder, is up nearly 8% despite a 44% revenue decrease to $8.8 million and a net loss of $64.7 million in Q1 2025.

Analysis

Several companies in the biotech and healthcare sectors reported significant developments and financial results, influencing their stock performance. Biodesix, Inc. (BDSX) experienced an over 80% stock increase, driven by a 21% year-over-year revenue growth to $18.0 million in Q1 2025 and a narrowed net loss of $11.1 million, down from $13.6 million. The company's positive outlook is further supported by its full-year 2025 revenue guidance of $80-$85 million, compared to $71.3 million in 2024. Apollomics Inc. (APLM) shares rose nearly 30% following a strategic collaboration with LaunXP for its Vebreltinib drug candidate, which includes a $10 million upfront payment and potential for up to $50 million in milestones, alongside anticipated data updates for APL-122 and APL-102 in 2025. Immuncell Corporation (ICCC), an animal health company, saw its shares climb over 14% after reporting record Q1 2025 product sales of $8.1 million, an 11% increase from the prior year, and a shift to a net income of $1.4 million from a net loss of $0.43 million, with gross margins improving to 42%. TransCode Therapeutics Inc. (RNAZ) shares increased over 15% after announcing the successful completion of initial dosing in Cohort 4 of its Phase 1a clinical trial for TTX-MC138; the company also effected a 1-for-28 reverse stock split to meet Nasdaq's minimum bid price requirement. Conversely, Semler Scientific, Inc. (SMLR) reported a 44% decrease in Q1 2025 revenue to $8.8 million and a substantial net loss of $64.7 million, a stark contrast to its net income of $6.1 million in Q1 2024, though its stock rose nearly 8%, potentially reflecting investor interest in its strategy of adopting bitcoin as its primary treasury reserve asset.

Key Decisions for Investors

• Investors should assess Biodesix's strong revenue growth, narrowing losses, and confident full-year guidance as indicators of improving fundamental strength.
• Apollomics Inc. warrants close observation for potential value inflection points stemming from its Vebreltinib collaboration and upcoming 2025 clinical trial data releases for APL-122 and APL-102.
• Consider Immuncell Corporation's record sales, return to profitability, and enhanced gross margins as evidence of successful operational execution, while also noting its plans to manage development expenses and expand capacity.
• Approach TransCode Therapeutics by balancing the positive progress in its Phase 1a clinical trial for TTX-MC138 against the cautionary signal of its recent reverse stock split undertaken for Nasdaq compliance.
• For Semler Scientific, it is crucial to weigh the significant deterioration in its core operational revenue and profitability against the potential benefits and considerable risks associated with its bitcoin-centric treasury strategy.